Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 200

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma

Open access
Kim, Nalee, Cheng, Jason, Jung, Inkyung, Liang, Ja Der, Shih, Yu Lueng, Huang, Wen-Yen, Kimura, Tomoki, Lee, Victor H.F., Zeng, Zhao Chong, Zhenggan, Ren, Kay, Chul Seung, Heo, Seok Jae, Won, Jong Yoon, Seong, Jinsil · 2020 · Journal of Hepatology

Abstract

BACKGROUND & AIMS In this multinational study, we compared the effectiveness of stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA) in HCC patients treated at seven hospitals. METHODS The retrospective study cohort included 2064 patients: 1568 and 496 in the RFA and SBRT groups, respectively. More than half of the patients (56.5%) developed recurrent tumors, mainly after transarterial chemoembolization (44.8%). Propensity score matching was performed to adjust for clinical factors (n=313 in each group). RESULTS At baseline, the SBRT group had unfavorable clinical features compared to the RFA group, including BCLC stage (B-C, 65% vs. 16%), tumor size (median, 3.0 vs. 1.9 cm), and frequent history of liver-directed treatment (81% vs. 49%, all p<0.001). With a median follow-up of 27.7 months, the 3-year cumulative local recurrence rate (CLRR) in the SBRT and RFA groups were 21.2% and 27.9%, respectively (p<0.001). After adjusting for clinical factors, SBRT was related to a significantly lower risk of local recurrence than RFA in both the entire (hazard ratio [HR] 0.45, p<0.001) and matched (HR 0.36, p<0.001) cohorts. Large tumor size (>3 cm), subphrenic location, and recurrence after transarterial chemoembolization were associated with superior local control in the SBRT group. Acute grade 3+ toxicities occurred in 1.6% and 2.6% of the SBRT and RFA patients, respectively (p=0.268). CONCLUSIONS SBRT could be an effective alternative to RFA for unresectable HCC when considering tumor size (>3 cm) and subphrenic region, and particularly for those tumors that progress after transarterial chemoembolization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.03.005

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 200

Metadata

Authors
Kim, N., Cheng, J., Jung, I., Liang, J. D., Shih, Y. L., Huang, W.-Y., Kimura, T., Lee, V. H. F., Zeng, Z. C., Zhenggan, R., Kay, C. S., Heo, S. J., Won, J. Y., & Seong, J.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-07
Volume
73
Issue
1
Pages
121-129
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3012452195
Cited by
200
References
1
FWCI
16.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. https://app.cochat.ai/papers/10.1016/j.jhep.2020.03.005
The paper
Kim, N., Cheng, J., Jung, I., Liang, J. D., Shih, Y. L., Huang, W.-Y., Kimura, T., Lee, V. H. F., Zeng, Z. C., Zhenggan, R., Kay, C. S., Heo, S. J., Won, J. Y., & Seong, J. (2020). Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.03.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.